Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide.
Tiong IS, Stevenson WS, Wall M, Yap YZ, Seymour JF, Kenealy M, Blombery P; Australasian Leukaemia & Lymphoma Group. Tiong IS, et al. Among authors: kenealy m. EJHaem. 2023 Aug 25;4(4):1212-1215. doi: 10.1002/jha2.767. eCollection 2023 Nov. EJHaem. 2023. PMID: 38024610 Free PMC article. No abstract available.
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia.
Kenealy M, Hertzberg M, Benson W, Taylor K, Cunningham I, Stevenson W, Hiwase D, Eek R, Zantomio D, Jong S, Wall M, Blombery P, Gerber T, Debrincat M, Zannino D, Seymour JF. Kenealy M, et al. Haematologica. 2019 Apr;104(4):700-709. doi: 10.3324/haematol.2018.201152. Epub 2018 Dec 13. Haematologica. 2019. PMID: 30545923 Free PMC article. Clinical Trial.
Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.
McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R; Australasian Leukaemia and Lymphoma Group (ALLG). McQuilten ZK, et al. Among authors: kenealy m. Leuk Lymphoma. 2022 Mar;63(3):676-683. doi: 10.1080/10428194.2021.2012664. Epub 2021 Dec 17. Leuk Lymphoma. 2022. PMID: 34915809
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML).
Kenealy M, Patton N, Filshie R, Nicol A, Ho SJ, Hertzberg M, Mills T, Prosser I, Link E, Cowan L, Zannino D, Seymour JF. Kenealy M, et al. Leuk Lymphoma. 2017 Feb;58(2):298-307. doi: 10.1080/10428194.2016.1190971. Epub 2016 Jun 7. Leuk Lymphoma. 2017. PMID: 27268068 Clinical Trial.
Treatment of chronic myelomonocytic leukemia with azacitidine.
Wong E, Seymour JF, Kenealy M, Westerman D, Herbert K, Dickinson M. Wong E, et al. Among authors: kenealy m. Leuk Lymphoma. 2013 Apr;54(4):878-80. doi: 10.3109/10428194.2012.730615. Epub 2012 Oct 5. Leuk Lymphoma. 2013. PMID: 22988826 No abstract available.
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN. Lane SW, et al. Among authors: kenealy m. Leuk Lymphoma. 2006 Sep;47(9):1813-7. doi: 10.1080/10428190600632832. Leuk Lymphoma. 2006. PMID: 17064993
33 results